Drug Class
BTK inhibitor
Type
brand
Active Ingredient
zanubrutinib
📋Overview
Brukinsa is a medication classified as a Bruton’s tyrosine kinase (BTK) inhibitor. It is primarily associated with the treatment of certain blood cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia. By targeting specific proteins involved in cancer cell growth, Brukinsa helps to slow the progression of these diseases. It is used in cases where these cancers affect the lymphatic system and blood.
📚References
Information from MedlinePlus.gov (NIH).
Found an Error?
Help us keep this information accurate. If you notice any incorrect details, please submit a correction request.
Find Discounts for Brukinsa
Hospitals.net Disclosure
Hospitals.net is an independent healthcare information platform and does not provide, administer, or guarantee prescription discounts, pricing, coupons, or pharmacy participation. All discount pricing and availability shown above are provided by RxGo and its partners and are subject to change without notice.
Hospitals.net may receive a commission or referral fee if you choose to use this prescription discount service. This does not affect the price you pay at the pharmacy. Hospitals.net is not responsible for pricing accuracy, pharmacy participation, or the fulfillment of any discount offers.